Dr. Reddy's Laboratories Ltd. (RDY)

38.20
0.01 0.03
NYSE : Health Technology
Prev Close 38.21
Open 38.52
Day Low/High 37.98 / 38.70
52 Wk Low/High 31.58 / 42.82
Volume 62.82K
Avg Volume 186.50K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 6.32B
EPS 1.60
P/E Ratio 23.45
Div & Yield 0.26 (0.68%)

Ratings Changes Today

Upgrades: CHRW, CPWR, ECA, FENG, SMIT, SUNS, TOF, ZTS Downgrades: AMRI, CDI, CWCO, EGY, ESIO, IFON, OESX, RDY, SLRC, TRR Initiations: JMI Read on to get TheStreet Quant Ratings' detailed report:

Senior Level Changes At Dr. Reddy’s

Senior Level Changes At Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Q4 & FY14 Financial Results

Dr. Reddy’s Q4 & FY14 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's To Release Q4 And Full Year FY14 Results On May 13, 2014

Dr. Reddy's To Release Q4 And Full Year FY14 Results On May 13, 2014

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2014 on Tuesday, May 13, 2014 after the Board Meeting.

Try these 7 rallying Indian stocks as country gears up for elections

Try these 7 rallying Indian stocks as country gears up for elections

James Dennin, Kapitall: Could these 7 rallying Indian stocks keep their momentum through election season, or do they portend correction? The [...]

Dr. Reddy’s Announces The Launch Of Fenofibrate Capsules, USP 43 Mg And 130 Mg

Dr. Reddy’s Announces The Launch Of Fenofibrate Capsules, USP 43 Mg And 130 Mg

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Fenofibrate Capsules, USP 43 mg and 130 mg a therapeutic equivalent generic version of ANTARA ® (fenofibrate) capsules, in the US...

Dr. Reddy’s Announces The Launch Of Eszopiclone Tablets C-IV

Dr. Reddy’s Announces The Launch Of Eszopiclone Tablets C-IV

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA® (eszopiclone) tablets C-IV in the ...

Dr. Reddy Laboratories Ltd. Stock Upgraded (RDY)

Dr. Reddy Laboratories Ltd. Stock Upgraded (RDY)

Dr. Reddy Laboratories (NYSE:RDY) has been upgraded by TheStreet Ratings from a hold to buy.

Ratings Changes Today

Upgrades: EPIQ, EXAR, GCAP, RDY Downgrades: EXA, IDRA, NCMI, PENN, SLW Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy’s Announces The Launch Of Amlodipine Besylate And Atorvastatin Calcium Tablets

Dr. Reddy’s Announces The Launch Of Amlodipine Besylate And Atorvastatin Calcium Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Amlodipine Besylate and Atorvastatin Calcium Tablets 2.

Dr. Reddy’s Announces The Launch Of Moxifloxacin Hydrochloride Tablets

Dr. Reddy’s Announces The Launch Of Moxifloxacin Hydrochloride Tablets

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Announces The Launch Of Sumatriptan Injection USP, Autoinjector System

Dr. Reddy’s Announces The Launch Of Sumatriptan Injection USP, Autoinjector System

Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.

New Lifetime High For Dr. Reddy Laboratories (RDY)

New Lifetime High For Dr. Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr. Reddy Laboratories (RDY) as a new lifetime high candidate

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Dr. Reddy Laboratories Ltd. Stock Downgraded (RDY)

Dr. Reddy Laboratories Ltd. Stock Downgraded (RDY)

Dr. Reddy Laboratories (NYSE:RDY) has been downgraded by TheStreet Ratings from from a buy to hold.

Ratings Changes Today

Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy’s Q3 & 9 Months FY14 Financial Results

Dr. Reddy’s Q3 & 9 Months FY14 Financial Results

Dr. Reddy’s Laboratories Ltd.

New Lifetime High For Dr. Reddy Laboratories (RDY)

New Lifetime High For Dr. Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr. Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's To Release Q3 FY14 Results On February 11, 2014

Dr. Reddy's To Release Q3 FY14 Results On February 11, 2014

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Third Quarter ended December 31, 2013 on Tuesday, February 11, 2014 after the Board Meeting.

Dr. Reddy’s Q2 & H1 FY14 Financial Results

Dr. Reddy’s Q2 & H1 FY14 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's To Release Q2 And Half Year FY14 Results On October 31, 2013

Dr. Reddy's To Release Q2 And Half Year FY14 Results On October 31, 2013

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half Year ended September 30, 2013 on Thursday, October 31, 2013 after the Board Meeting.

Dr. Reddy’s Announces The Approval Of Azacitidine For Injection

Dr. Reddy’s Announces The Approval Of Azacitidine For Injection

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA ® (azacitidine for injection), is approved by the United States Food ...

Ratings Changes Today

Upgrades: FSM, LND, RDY, SGMA Downgrades: ABMD, HOLX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Infosys, Tata Ready for Takeoff

Infosys, Tata Ready for Takeoff

Indian exporters such as Infosys, Tata Motors and Dr. Reddy's are benefitting from global market trends, says Kunal Ghosh, Portfolio Manager for the AllianzGI Emerging Markets Opportunities Fund.

Dr. Reddy’s Announces The Launch Of Divalproex Sodium Extended - Release Tablets, USP

Dr. Reddy’s Announces The Launch Of Divalproex Sodium Extended - Release Tablets, USP

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Divalproex Sodium Extended - Release Tablets, USP (250 mg and 500 mg), a therapeutic equivalent generic version of Depakote ® ER...

Dr. Reddy’s Appoints Dr. Sripada Chandrasekhar As President And Global Head Of Human Resources

Dr. Reddy’s Appoints Dr. Sripada Chandrasekhar As President And Global Head Of Human Resources

Dr. Reddy’s has announced the appointment of Dr.

Ratings Changes To Be Publicly Issued on 8/1/13

Upgrades: ARE, BBOX, BFS, CAFI, ELGX, HT, LBY, LMNX, MAS, SEM, TFSL, UMH, VSB Downgrades: ADVS, RDY, UDR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Dr. Reddy’s Q1 FY14 Financial Results

Dr. Reddy’s Q1 FY14 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Announces The Launch Of Donepezil Hydrochloride Tablets, 23 Mg

Dr. Reddy’s Announces The Launch Of Donepezil Hydrochloride Tablets, 23 Mg

Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched Donepezil Hydrochloride Tablets, 23 mg, a therapeutic equivalent generic version of ARICEPT ®, 23 mg in the U.

TheStreet Quant Rating: B- (Buy)